Moreover, the intravenous administration of HUCDMSCs provided a significant amelioration of glomerular abnormalities and interstitial fibrosis in a mouse model of STZ-induced diabetes without affecting hyperglycemia, regardless of whether administered early or late in the disease course, which was associated with reduced circulating TGF-β1 levels and restoration of intra-renal autophagy [268]. Here, TGFB1 is linked to diabetes mellitus.